Category: Pharma
-
NanoViricides Recent Clinical Updates and Milestones Highlight Potential Investor Opportunities
NanoViricides, Inc. (NYSE American: NNVC), a pioneering, clinical-stage biopharmaceutical company, is disrupting the antiviral game with its innovative, first-in-class, nanoviricides® technology.
-
Decoded: Why Did Johnson & Johnson Spend $2 billion To Acquire Ambrx Biopharma?
In a groundbreaking move, pharmaceutical giant Johnson & Johnson has set the stage for a significant leap forward in cancer treatment with its recent $2 billion acquisition of Ambrx Biopharma.
-
TG Therapeutics: Is It Time to Invest In This Biotech Player After The Unprecedented 36.4% Jump?
TG Therapeutics’ stock soared an astonishing 36.4% higher in a single session on the heels of the company’s impressive third-quarter results.
-
NanoViricides Gets Big Funding Boost From CEO Dr. Anil Diwan Prior To IND Application
Based in Connecticut, NanoViricides is a growth stage firm that’s at superior levels of trials with respect to a number of drug candidates and is looking out for funding on occasion for its analysis. This time the funding has come from Dr. Diwan himself and it’s within the type of a $2 million dedication of…
-
NanoViricides: Grab This Biopharma Player While Inexpensive
Investment timing is among the most important ideas associated to the world of stock market investing. While its software is essential for investments throughout any and each sector, one specific business the place it’s most related is the biotech business. Often, we see biotech firms with minimal revenues which can be on the verge of…
-
1globe Capital Llc. Picked Up Exelixis Inc. (NASDAQ:EXEL) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Exelixis Inc. (NASDAQ:EXEL) reported that 1globe Capital Llc. has picked up 5,437,285 of common stock as of 2017-02-15. The acquisition brings the aggregate amount owned by 1globe Capital Llc. to a total of 5,437,285 representing a 1.9% stake in the…